Patents by Inventor Xingxing Zang

Xingxing Zang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTAGONIST ANTIBODIES AGAINST HUMAN IMMUNE CHECKPOINT CEACAM1 (CD66a) AND FORMULATIONS, KITS, AND METHODS OF USE THEREOF
    Publication number: 20230116037
    Abstract: Provided are isolated antibodies and antigen-binding fragments thereof that specifically bind CEACAM1, including the IgV domain of CEACAM1, as well as pharmaceutical formulations, kits, and methods of use thereof.
    Type: Application
    Filed: June 29, 2022
    Publication date: April 13, 2023
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE
    Inventor: Xingxing ZANG
  • HHLA2 AS A NOVEL INHIBITOR OF HUMAN IMMUNE SYSTEM AND USES THEREOF
    Publication number: 20230076027
    Abstract: Provided are methods of treating an autoimmune disease in a subject, or of suppressing transplant rejection in a subject, or of treating a cancer in a subject, as well as compositions therefor.
    Type: Application
    Filed: September 15, 2022
    Publication date: March 9, 2023
    Inventor: Xingxing ZANG
  • KIR3DL3 IS AN INHIBITORY RECEPTOR OF THE IMMUNE SYSTEM AND USES THEREOF
    Publication number: 20230040568
    Abstract: Described herein are antibodies, immunogenic fragments and compositions thereof targeting the killer-cell immunoglobulin-like receptor protein KIR3DL3, as well as methods of using the same for the treatment of human diseases including cancer. In certain embodiments, the disclosure relates to an antibody or an immunogenic fragment thereof that specifically binds to KIR3DL3 protein, wherein the antibody or the immunogenic fragment thereof specifically binds to a KIR3DL3 epitope comprising the whole extracellular domain or a portion thereof.
    Type: Application
    Filed: October 1, 2020
    Publication date: February 9, 2023
    Inventors: Xingxing ZANG, Yao WEI, Xiaoxin REN, Scott MOERDLER
  • HHLA2 AS A NOVEL INHIBITOR OF HUMAN IMMUNE SYSTEM AND USES THEREOF
    Publication number: 20230002491
    Abstract: Provided are methods of treating an autoimmune disease in a subject, or of suppressing transplant rejection in a subject, or of treating a cancer in a subject, as well as compositions therefor.
    Type: Application
    Filed: January 24, 2022
    Publication date: January 5, 2023
    Inventor: Xingxing ZANG
  • Antagonist antibodies against human immune checkpoint CEACAM1 (CD66a) and formulations, kits, and methods of use thereof
    Patent number: 11377494
    Abstract: Provided are isolated antibodies and antigen-binding fragments thereof that specifically bind CEACAM1, including the IgV domain of CEACAM1, as well as pharmaceutical formulations, kits, and methods of use thereof.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: July 5, 2022
    Assignee: Albert Einstein College of Medicine
    Inventor: Xingxing Zang
  • HHLA2 as a novel inhibitor of human immune system and uses thereof
    Patent number: 11261253
    Abstract: Provided are methods of treating an autoimmune disease in a subject, or of suppressing transplant rejection in a subject, or of treating a cancer in a subject, as well as compositions therefor.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: March 1, 2022
    Assignee: Albert Einstein College of Medicine
    Inventor: Xingxing Zang
  • MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF
    Publication number: 20220010018
    Abstract: The present disclosure provides monoclonal antibodies that bind to an IgV domain of human B7-H3. Also provided are methods of using these antibodies in treating cancer and infection and in imaging B7-H3 positive cells.
    Type: Application
    Filed: November 15, 2019
    Publication date: January 13, 2022
    Inventor: Xingxing ZANG
  • TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESSED HHLA2 FOR IMMUNOTHERAPIES
    Publication number: 20210388052
    Abstract: Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.
    Type: Application
    Filed: January 4, 2021
    Publication date: December 16, 2021
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE
    Inventors: Xingxing Zang, Jordan M. Chinai, Murali Janakiram, Steven C. Almo, Andras Fiser
  • ANTAGONIST ANTIBODIES AGAINST HUMAN IMMUNE CHECKPOINT CEACAM1 (CD66a) AND FORMULATIONS, KITS, AND METHODS OF USE THEREOF
    Publication number: 20210380687
    Abstract: Provided are isolated antibodies and antigen-binding fragments thereof that specifically bind CEACAM1, including the IgV domain of CEACAM1, as well as pharmaceutical formulations, kits, and methods of use thereof.
    Type: Application
    Filed: December 20, 2019
    Publication date: December 9, 2021
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE
    Inventor: Xingxing ZANG
  • MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3
    Publication number: 20210198357
    Abstract: Provided are anti-human Tim-3 IgV domain-specific antibodies and fragments thereof, as well as methods of use employing such antibodies and/or fragments.
    Type: Application
    Filed: August 21, 2019
    Publication date: July 1, 2021
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE
    Inventor: Xingxing ZANG
  • TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies
    Patent number: 10882893
    Abstract: Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: January 5, 2021
    Assignee: Albert Einstein College of Medicine
    Inventors: Xingxing Zang, Jordan M. Chinai, Murali Janakiram, Steven C. Almo, Andras Fiser
  • ANTIBODIES TO HUMAN B7X FOR TREATMENT OF METASTATIC CANCER
    Publication number: 20200392246
    Abstract: Methods are provided for treating metastatic cancer in patients having metastatic cancer or for preventing metastasis in cancer patients at risk for metastasis comprising administering to the patient an antibody to B7x, or an active antibody fragment that binds B7x, in an amount effective to treat or prevent metastasis.
    Type: Application
    Filed: August 27, 2020
    Publication date: December 17, 2020
    Inventors: Xingxing ZANG, James P. ALLISON
  • BTNL9 AND ERMAP AS NOVEL INHIBITORS OF THE IMMUNE SYSTEM FOR IMMUNOTHERAPIES
    Publication number: 20200338161
    Abstract: Provided are methods of treating a tumor in a subject with a BTNL9-binding antibody. Also provided are methods of treating a tumor in a subject with an ERMAP-binding antibody. A fusion protein comprising a BTNL9 or ERMAP and related compositions and encoding nucleic acids are also provided.
    Type: Application
    Filed: May 5, 2020
    Publication date: October 29, 2020
    Applicant: Albert Einstein College of Medicine
    Inventors: Xingxing ZANG, Kaya GHOSH
  • B7X and its derivatives for treating and preventing cardiovascular disease
    Patent number: 10689432
    Abstract: Methods are disclosed for preventing and/or treating cardiovascular diseases comprising administering B7x or a derivative of B7x to a patient in need thereof.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: June 23, 2020
    Assignee: Albert Einstein College of Medicine
    Inventors: Xingxing Zang, Hyungjun Jeon
  • TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESSED HHLA2 FOR IMMUNOTHERAPIES
    Publication number: 20190263886
    Abstract: Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.
    Type: Application
    Filed: March 13, 2019
    Publication date: August 29, 2019
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE
    Inventors: Xingxing Zang, Jordan M. Chinai, Murali Janakiram, Steven C. Almo, Andras Fiser
  • TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies
    Patent number: 10280208
    Abstract: Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: May 7, 2019
    Assignee: Albert Einstein College of Medicine
    Inventors: Xingxing Zang, Jordan M. Chinai, Murali Janakiram, Steven C. Almo, Andras Fiser
  • HHLA2 AS A NOVEL INHIBITOR OF HUMAN IMMUNE SYSTEM AND USES THEREOF
    Publication number: 20190010234
    Abstract: Provided are methods of treating an autoimmune disease in a subject, or of suppressing transplant rejection in a subject, or of treating a cancer in a subject, as well as compositions therefor.
    Type: Application
    Filed: September 5, 2018
    Publication date: January 10, 2019
    Applicant: ALBERT EINSTEIN COLLGE OF MEDICINE, INC.
    Inventor: Xingxing Zang
  • BTNL9 AND ERMAP AS NOVEL INHIBITORS OF THE IMMUNE SYSTEM FOR IMMUNOTHERAPIES
    Publication number: 20180296636
    Abstract: Provided are methods of treating a tumor in a subject with a BTNL9-binding antibody. Also provided are methods of treating a tumor in a subject with an ERMAP-binding antibody. A fusion protein comprising a BTNL9 or ERMAP and related compositions and encoding nucleic acids are also provided.
    Type: Application
    Filed: November 12, 2015
    Publication date: October 18, 2018
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
    Inventors: Xingxing Zang, Kaya Ghosh
  • HHLA2 as a novel inhibitor of human immune system and uses thereof
    Patent number: 10093737
    Abstract: Provided are methods of treating an autoimmune disease in a subject, or of suppressing transplant rejection in a subject, or of treating a cancer in a subject, as well as compositions therefor.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: October 9, 2018
    Assignee: Albert Einstein College of Medicine, Inc.
    Inventor: Xingxing Zang
  • TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESSED HHLA2 FOR IMMUNOTHERAPIES
    Publication number: 20170174742
    Abstract: Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.
    Type: Application
    Filed: April 24, 2015
    Publication date: June 22, 2017
    Inventors: Xingxing Zang, Jordan M. Chinai, Murali Janakiram, Steven C. Almo, Andras Fiser